BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.

[14][15] The company's origins lie in research conducted by Şahin, Türeci, and their teams, who over several decades made progress in addressing challenges using messenger RNA (mRNA) as a therapeutic.

[27] Since 10 October 2019, BioNTech has been publicly traded as American Depository Shares (ADS) on the NASDAQ Global Select Market under the ticker symbol BNTX.

In August 2021, thanks to a meteoric rise in its share price, BioNTech’s market capitalization briefly exceeded US$100 billion, making it one of the most valuable companies in Germany at that time.

[43] Alongside ongoing development of COVID-19 vaccines, BioNTech expanded its oncology pipeline and drug manufacturing capabilities,[44][44][45] leading to an increasing number of trials in advanced clinical phases.

[45][46][47][48] The company has formed strategic collaborations and acquisitions to enhance its platform technologies, global manufacturing capacity, and computational drug discovery capabilities.

BioNTech had been collaborating with InstaDeep since 2019 on cancer drug design and expanded their partnership in 2022 to create an early warning system for detecting SARS-CoV-2 variants of concern.

[54] In 2023, BioNTech entered a collaboration with the UK government to expand access to personalized mRNA cancer immunotherapies in clinical trials, aiming to treat up to 10,000 patients by 2030.

[47][70][46] In November 2023, in an interview to German broadcaster ZDF, BioNTech CEO Uğur Şahin said the company expects a mRNA-based therapeutic cancer vaccine approval by 2030.

[72] BioNTech is developing mRNA-based vaccines for a range of infectious diseases with significant global health impact, including COVID-19, malaria, tuberculosis, and mpox.